November
17, 2009
|
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, NE
Washington,
D.C. 20549-6010
Attn:
Mr. Kevin L. Vaughn
|
Re:
|
Pressure BioSciences,
Inc.
Form 10-K for the year
ended December 31, 2008
File No.
0-21615
|
1.
|
SEC
Comment - Please
tell us and revise future filings to disclose your methodology for
determining lower of cost or market. In this regard, disclose
how you determine the cost basis. Refer to paragraph
330-10-50-1 of the FASB Accounting Standards
Codification.
|
2.
|
SEC
Comment - We note
that you utilize the Black-Scholes option pricing model to determine the
fair value of your equity-based compensation. Please revise
future filings to explain how you determined the assumptions utilized in
the model including the volatility, expected life, etc. Refer
to the guidance in 718-10-50-2f of the FASB Accounting Standard
Codification.
|
3.
|
SEC
Comment – We note
your disclosure that management has concluded that your disclosure
controls and procedures are effective “in enabling [you] to record,
process, summarize and report information required to be included in
[y]our periodic SEC filings within the required time
period.” The language that is currently included after the word
“effective” in your disclosure appears to be superfluous, since the
meaning of “disclosure controls and procedures” is established by Rule
13a-15(e) of the Exchange Act. However, if you do not wish to
eliminate this language, please revise future filings so that the language
that appears after the word “effective” is substantially similar in all
material respects to the language that appears in the entire two-sentence
definition of “disclosure controls and procedures” set forth in Rule
13a-15(e).
|
4.
|
SEC
Comment – We note
your statement that “ . . . any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives.” Please [revise] your
future filings to state clearly, if true, that your principal executive
officer and principal financial officer concluded that your disclosure
controls and procedures are effective at the reasonable assurance
level. In the alternative, please remove the reference to the
level of assurance of your disclosure controls and
procedures. Please refer to Section II.F.4 of Management’s
Reports on Internal Control Over Financial Reporting and Certification of
Disclosure in Exchange Act Periodic Reports. SEC Release No.
33-8238 on our website at
www.sec.gov/rules/final/33-8238.htm.
|
5.
|
SEC
Comment – We note
that the identification of the certifying individual at the beginning of
the certification required by Exchange Act Rule 13a-14(a) also includes
the title of the certifying individual. In future filings, the
identification of the certifying individual at the beginning of the
certification should be revised so as not to include the individual’s
title.
|
6.
|
SEC
Comment - We note
that your president and chief executive officer has provided the
certifications required by Item 601(b)(31) of the Regulation S-K in his
role as principal executive officer and principal financial
officer. However, we note that the certificate included in
Exhibit 31.2 is not in the proper form in that the reference to internal
control over financial reporting in the introductory language to paragraph
4 of the certificate has been omitted. Please ensure that all
certifications provided in future filings are in the exact form set forth
in Item 601(b)(31) of Regulation S-K. In this regard, please
note the guidance in SEC Compliance and Disclosure Interpretation 161.03,
which indicates that if the same individual is both the principal
executive officer and the principal financial officer, that individual may
provide just one certification and provide both titles underneath the
signature.
|
7.
|
SEC
Comment - We note
that you sold 156,980 preferred stock units in February
2009. We further note that you valued the warrants using the
Black Scholes model. Please address the
following:
|
|
·
|
Tell us and revise your future
filings to disclose all significant assumptions you used in determining
the value of the warrants you
issued.
|
|
·
|
Further to the above, discuss
how you considered the $489,803 deemed dividend in your earnings per share
presentation on pages 2 and 7. Refer to paragraph 260-10-45 11
of the FASB Accounting Standards
Codification.
|
Preferred
|
Common
|
|||||||
Exercise
price
|
$ | 1.25 | $ | 2.00 | ||||
Stock
price
|
$ | 0.90 | $ | 0.90 | ||||
Volatility
|
142 | % | 109 | % | ||||
Life
of warrant
(in months) |
15 | 30 | ||||||
Treasury
rate
|
0.875 | % | 1.375 | % | ||||
Fair
value per warrant
|
$ | 0.45 | $ | 0.41 |
November
17, 2009
|
US
Securities and Exchange Commission
Division
of Corporate Finance
100
F Street N.E
Washington
DC 20549
Attn:
Mr. Kevin L. Vaughn
|
Re:
|
Pressure BioSciences,
Inc.
Form 10-K for the year
ended December 31, 2008
File No.
0-21615
|
Yours
sincerely,
|
/s/
Richard T. Schumacher
|
President,
Chief Executive Officer and
Treasurer
|